Premium
Ethanol preconditioning protects against ischemia/reperfusion‐induced cardiac damage via calcitonin gene‐related peptide and is initiated by a transient receptor potential vanilloid 1‐dependent mechanism
Author(s) -
Wang Meifang,
Zuidema Mozow Y.,
Korthuis Ronald J.
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.678.5
Subject(s) - calcitonin gene related peptide , trpv1 , capsazepine , ischemia , chemistry , reperfusion injury , medicine , troponin i , pharmacology , endocrinology , ethanol , receptor , anesthesia , transient receptor potential channel , neuropeptide , biochemistry , myocardial infarction
Our previous studies indicated that ingestion of ethanol at low to moderate levels prior to ischemia/reperfusion (I/R) protects against postischemic intestinal and cerebral injury. These protective actions are initiated by a calcitonin gene‐related peptide (CGRP)/ transient receptor potential vanilloid 1 (TRPV1) ‐ dependent mechanism. This study was to determine whether a similar mechanism underlies the protective effect of ethanol preconditioning in cardiac I/R injury. Serum Troponin‐I (cTnI), a marker of myocardial injury, was markedly elevated in wild type male C57BL/6J mice after 30 min left anterior descending (LAD) ischemia and 4 h reperfusion, at which cTnI reaches its peak level. When mice were treated with ethanol 24 h prior to cardiac I/R as a bolus by gavage (at a dose that produces peak plasma ethanol of 40–45 mg/dl), cTnI levels did not increase in comparison to I/R alone (p<0.001). This protective effect of ethanol consumption was significantly attenuated by administration of capsazepine, a competitive TRPV1 antagonist 10 min before ethanol ingestion (p<0.05). These findings demonstrate the protection against cardiac I/R from antecedent ethanol ingestion occurs via a TRPV1‐dependent mechanism. Supported by a grant from the NIH (AA‐014945).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom